Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Presentation TCT 2017

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Presenter: Gregg W. Stone, Peter H. Stone, Jung-Min Ahn

November 01, 2017

TCT 9: Absorb Bioresorbable Vascular Scaffold vs Everolimus-Eluting Metallic Stent in Small Vessel Disease -A Propensity Matched Analysis of COMPARE II, RAI, and MAASSTAD-ABSORB Prospective Studies

Presentation TCT 2017

TCT 9: Absorb Bioresorbable Vascular Scaffold vs Everolimus-Eluting Metallic Stent in Small Vessel Disease -A Propensity Matched Analysis of COMPARE II, RAI, and MAASSTAD-ABSORB Prospective Studies

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Alberto Barioli, MD

October 31, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

DESolve Bioresorbable Stent Compares Well With Absorb but Longer Follow-up Needed

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.